Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13665MR)

This product GTTS-WQ13665MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13665MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3912MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ1885MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ15385MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ14341MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ4277MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ7837MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ12989MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ9932MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW